SCHEMBL5734390

SCHEMBL5734390

COP(=O)(CC(=O)c1ccc(Oc2ccccc2)cc1)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.57
LMNA P02545 1/20 0.57
ERCC5 P28715 1/20 0.54
FEN1 P39748 1/20 0.54
MMP1 P03956 2/20 0.50
PARP10 Q53GL7 1/20 0.49
SRD5A2 P31213 3/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MMP2 P08253 1/20 0.47
CA9 Q16790 1/20 0.47
MAPK14 Q16539 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HDAC3 O15379 1/20 0.46
HPGD P15428 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734842 0.87 POLB (0.73) POLBLMNAHPGDNPC1RAB9A
SCHEMBL5733091 0.87 ERCC5 (0.57) POLBLMNAERCC5FEN1PARP10
SCHEMBL14105322 0.84 LMNA (0.60) POLBLMNAERCC5FEN1CYP1A2
SCHEMBL10357072 0.78 LMNA (0.51) POLBLMNANPC1RAB9ASMN1; SMN2
SCHEMBL5733603 0.78 PTPN1 (0.54) POLBLMNAHDAC3HPGDNPC1
SCHEMBL5734397 0.78 ERCC5 (0.50) POLBLMNAERCC5FEN1MMP1
SCHEMBL9257364 0.77 LMNA (0.50) POLBLMNAERCC5FEN1HPGD
SCHEMBL28441720 0.77 ERCC5 (0.60) POLBLMNAERCC5FEN1MMP1
SCHEMBL9548021 0.77 GSK3B (0.50) POLBLMNACA12MMP2CYP1A2
SCHEMBL2322443 0.77 LMNA (0.50) POLBLMNACA1CA2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 EP disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 POLB 3426/4885LMNA 3569/4885ERCC5 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.